Holen Sie sich die Stockscreener-App
131.02
0.26%
-0.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$131.36
Offen:
$131.74
24-Stunden-Volumen:
5.66M
Relative Volume:
0.87
Marktkapitalisierung:
$228.03B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$13.98B
KGV:
16.42
EPS:
7.98
Netto-Cashflow:
$6.78B
1W Leistung:
+0.25%
1M Leistung:
-0.76%
6M Leistung:
+0.41%
1J Leistung:
+21.54%
1-Tages-Spanne:
$129.62
$131.89
1-Wochen-Bereich:
$129.62
$134.71
52-Wochen-Spanne:
$107.60
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
131.02 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.64 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.61 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.08 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.93 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Chris Blumas' Past Picks: Brookfield Corp, Abbott Labs & Great-West Lifeco - BNN Bloomberg
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK - Yahoo Finance
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - GlobeNewswire Inc.
Abbott India's profit climbs on healthy pharmaceutical demand - Reuters
Top Abbott Executive Makes Significant Stock Sale! - TipRanks
Abbott Shakes Suit Over Meta, Google Data Sharing For Now - Law360
Abbott Laboratories poised to end in red after six-session rally - MSN
Abbott Labs Beats Class Action Over Meta, Google Info Sharing - Bloomberg Law News
Abbott Laboratories shows growth in core products amid market shifts - Yahoo Finance
Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb Or Sink? - Barchart.com
Abbott Laboratories maintains steady performance amid market shifts - Express Healthcare
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories Q2 Earnings: Dividends Don’t Lie (NYSE:ABT) - Seeking Alpha
Do New Glucose Monitoring Launches Signal Sustainable Profit Growth for Abbott (ABT)? - simplywall.st
Abbott Laboratories shares rise 1.11% intraday as Senseonics Holdings, Inc. reports Q2 revenue up 37%. - AInvest
Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters - Reuters
Abbott launches next-gen MitraClip, TriClip G5 systems - MassDevice
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Abbott Laboratories' Earnings Raise Concerns Despite Strong Profit Numbers - AInvest
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It? - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) Earnings Are Of Questionable Quality - Yahoo Finance
Arterial Stents Market Surge to 2035: Growth Driven by Abbott, Boston Scientific, BIOTRONIK & Biosensors - openPR.com
Medical Devices & SuppliesDiversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Is a Favorite Amongst Institutional Investors Who Own 80% - 富途牛牛
What institutional investors are buying Abbott Laboratories stockOutstanding trading profits - Jammu Links News
What is the dividend policy of Abbott Laboratories stockFree Stock Chart Pattern Guide - Jammu Links News
Is it the right time to buy Abbott Laboratories stockTremendous wealth creation - Jammu Links News
How does Abbott Laboratories compare to its industry peersMaximize portfolio growth with professional advice - Jammu Links News
Abbott Laboratories Stock Analysis and ForecastCapitalize on momentum-driven opportunities - Jammu Links News
When is Abbott Laboratories stock expected to show significant growthConsistent high-performance stocks - jammulinksnews.com
UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating - MSN
Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - simplywall.st
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Strong Fundamentals and Technical Uncertainty - AInvest
Similac NEC Lawsuit: 2025 Updates & List of Affected Formulas - Drugwatch.com
What makes Abbott Laboratories stock price move sharplyPotential Breakout Stock List Published This Week - metal.it
Abbott Laboratories Shares Drop 1.84 as Analysts Clash on Value Amid $850M Volume 155th in Market Activity - AInvest
How volatile is Abbott Laboratories stock compared to the marketMarket Forecast Signals For Fast Growth - Jammu Links News
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Why Abbott Laboratories (ABT) Remains a Buy Despite Diagnostic Segment Weakness - AInvest
Abbott Laboratories 2025 Q2 Earnings Strong Performance as Net Income Climbs 36.6% - AInvest
Biotechnology Market is evolving rapidly Through 2025 To 2032 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Abbott Gains 1.31% Amid 140th Trading Volume Rank as Analysts Weigh Diagnostic Sector Growth and Competitive Risks - AInvest
Meal Replacement Market Is Booming Worldwide 2025-2032 | Abbott - openPR.com
Paul MacDonald's Top Picks: Stryker, Abbott Labs & Elevance Health - BNN Bloomberg
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche - Yahoo Finance
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - MSN
2nd Abbott Baby Formula Bellwether Falls Before Trial - Law360
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):